



MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 1, 2006 (use as many sheets as necessary)			Complete if Known		
			Application Number	Unassigned	
Sheet	1	of	1	Filing Date	3/11/2005
				First Named Inventor	Christophe de ROMEUF
				Group Art Unit	1644
				Examiner Name	C. Crowder
				Attorney Docket Number	065691-0388

U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
C.C.	A1	WO	01/77181		BELIARD et al.	10/18/2001	Abstract only	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
C.C.	A2	CROWE, J.S., et al.; Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material; Clin. Exp. Immunol. (1992) 87, 105-110.			
	A3	VIVIER, E., et al.; Signaling function of reconstituted CD16: ζ : γ : receptor complex isoforms; International Immunology (1992), Vol. 4, No. 11, pp. 1313-1323.			
	A4	ROUARD, H., et al.; Fc Receptors as Targets for Immunotherapy; Intern. Rev. Immunol. (1997), Vol. 16, pp. 147-185.			
	A5	LUND, J., et al.; A Protein Structural Change in Aglycosylated I _g G3 Correlates with Loss of huFc γ R1 and of huFc γ R111 Binding and/or Activation; Molecular Immunol. (1990), Vol. 27, pp. 1145-1153.			
	A6	LEATHERBARROW, R., et al.; Effector Functions of a Monoclonal Aglycosylated Mouse I _g G2 _b : Binding and Activation of Complement Component C1 and Interaction with Human Monocyte Fc Receptor; Molecular Immunol. (1985), Vol. 22, pp. 407-415.			
	A7	JEFFERIS, R., et al.; A Comparative Study of the N-linked Oligosaccharide Structures of Human I _g G Subclass Proteins; Intern. Biochem J. (1990), 268, pp. 529-537.			
C.C.	A8	PAREKH, R.B., et al.; Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum I _g G; Nature. (1985), Vol. 316, pp. 452-457.			

Examiner Signature		Date Considered	5/14/07
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.